Equivalence and noninferiority trials – are they viable alternatives for registration of new drugs? (III)

Hutton J, Borowitz M, Oleksy I, Luce BR: The pharmaceutical industry and health reform: lessons from Europe. Health Aff (Millwood). 1994, 13: 98-111. 10.1377/hlthaff.13.3.98. Williams A: The cost-benefit approach. Br Med Bull. 1974, 30: 252-256. Drummond MF, Stoddard GL, Torrance GW: Methods for the economic evaluation of health care programmes. 1997, Oxford: Oxford University Press Maynard A: The design of future cost-benefit studies. Am Heart J. 1990, 119 (3 Pt 2): 761-765. Spurgeon D: NIH promotes use of lower cost drugs for hypertension. BMJ. 2004, 328: 539-10.1136/bmj.328.7439.539. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288: 2981-2997. Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, Greenspan FS: Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA. 1997, 277: 1205-1213. 10.1001/jama.277.15.1205. Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR: Therapeutic bioequivalence study of brand name versus generic carbamazepine. Neurology. 1992, 42: 1147-1153. Oberlin O, Leverger G, Pacquement H, Raquin MA, Chompret A, Habrand JL: Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992, 10: 1602-1608. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996, 88: 890-899. 10.1093/jnci/88.13.890. Taggart SC, Custovic A, Richards DH, Woodcock A: GR106642X: a new, non-ozone depleting propellant for inhalers. BMJ. 1995, 310: 1639-1640. Edwards SJ, Lilford RJ, Braunholt DA, Jackson JC, Hewison J, Thornton J: Ethical issues in the design and conduct of randomised controlled trials. Health Technol Assess. 1998, 2: 1-132. Rothman KJ, Michels KB, Baum B: Declaration of Helsinki should be strengthened: for and against. BMJ. 2000, 321: 442-44514. 10.1136/bmj.321.7258.442. Mathe G, Brienza S: From methodology to ethics and from ethics to methodology. Biomed Pharmacother. 1988, 42: 143-153. Food and Drug Administration, Department of Health and Human Services: Guidance for industry: E 10: choice of control group and related issues in clinical trials. Rockville, Md. 2001 Ellenberg SS, Temple R: Placebo-controlled trials and active-control-trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med. 2000, 133: 464-70. Urquhart J: Demonstrating effectiveness in post-placebo era. Clin Pharmacol Ther. 2001, 70: 115-120. 10.1067/mcp.2001.117285. Rothman KJ, Michels KB: The continuing unethical use of placebo controls. N Engl J Med. 1994, 331: 394-398. 10.1056/NEJM199408113310611. Agostoni A: Placebo and EU guidelines [Letter]. Lancet. 1995, 346: 1710-10.1016/S0140-6736(95)92876-6. Aspinall RL, Goodman NW: Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. BMJ. 1995, 311: 844-846. Henry D, Hill S: Comparing treatments [Editorial]. BMJ. 1995, 310: 1279- Freedman B, Weijer C, Glass KC: Placebo orthodoxy in clinical research. I: Empirical and methodological myths. J Law Med Ethics. 1996, 24: 243-251. Freedman B, Weijer C, Glass KC: Placebo orthodoxy in clinical research. II: Ethical, legal, and regulatory myths. J Law Med Ethics. 1996, 24: 252-259. Angell M: The ethics of clinical research in the Third World [Editorial]. N Engl J Med. 1997, 337: 847-849. 10.1056/NEJM199709183371209. Garattini S, Bertele V: Adjusting Europe's drug regulations to public health needs. Lancet. 2001, 358: 64-67. 10.1016/S0140-6736(00)05258-2. Jones B, Jarvis P, Lewis JA: Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996, 313: 36-39. Ware JH, Antman EM: Equivalence trials. N Engl J Med. 1997, 337: 1159-1161. 10.1056/NEJM199710163371610. Ebbutt AF, Frith L: Practical issues in equivalence trials. Stat Med. 1998, 17: 1691-1701. 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1691::AID-SIM971>3.3.CO;2-A. Fleming TR: Design and interpretation of equivalence trials. Am Heart J. 2000, 139: S171-S176. 10.1016/S0002-8703(00)90067-X. Snapinn SM: Noninferiority trials. Curr Control Trials Cardiovasc. 2000, 1: 19-21. 10.1186/CVM-1-1-019. McAlister FA, Sackett DL: Active-control equivalence trials and antihypertensive agents. Am J Med. 2001, 111: 553-558. 10.1016/S0002-9343(01)00900-7. Wang S-J, Hung HMJ, Tsong Y: Utility and pitfalls of some statistical methods in active controlled clinical trials. Control Clin Trials. 2002, 23: 15-28. 10.1016/S0197-2456(01)00155-6. Greene Wl, Concato J, Feinstein AR: Claims of equivalence in medical research: are they supported by the evidence?. Ann Intern Med. 2000, 132: 715-722. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ: When placebo controlled trials are essential and equivalence trials are inadequate. BMJ. 1998, 317: 875-880. Max MB: Divergent traditions in analgesic clinical trials. Clin Pharmacol Ther. 1994, 56: 237-241. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985, 27: 335-71. Ernst E, Resch KL: Concept of true and perceived placebo effects. BMJ. 1995, 311: 551-553. Siegel JP: Equivalence and noninferiority trials. Am Heart J. 2000, 139: S166-70. 10.1016/S0002-8703(00)90066-8. Alderson P: Absence of evidence is not evidence of absence. BMJ. 2004, 328: 476-477. 10.1136/bmj.328.7438.476. Djulbegovic B, Clarke M: Scientific and ethical issues in equivalence trials. JAMA. 2001, 285: 1206-1208. 10.1001/jama.285.9.1206. Altman DG, Bland JM: Absence of evidence is not evidence of absence. BMJ. 1995, 311: 485- Probstfield JL: The clinical trial prerandomization compliance (adherence) screen. In: Patient compliance in medical practice and clinical trials. Edited by: Cramer JA, Spilker B. 1991, New York: Raven Press, 323-334. Knipschild P, Leffers P, Feinstein AR: The qualification period. J Clin Epidemiol. 1991, 44: 461-464. 10.1016/0895-4356(91)90208-Q. Urquhart J, de Klerk E: Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med. 1998, 17: 251-267. 10.1002/(SICI)1097-0258(19980215)17:3<251::AID-SIM762>3.3.CO;2-1. Vrijens B, Geotghebeur E: The impact of compliance in pharmacokinetic studies. Stat Methods Med Res. 1999, 8: 247-262. 10.1191/096228099669221405. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000, 133: 21-30. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995, 25: 305-313. Walley T, Duggan AK, HAycox AR, Noziol CJ: Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. J R Soc Med. 2003, 96: 525-531. 10.1258/jrsm.96.11.525. Rand CS: I took the medicine like you told me, doctor: self-report of adherence to medical regimens. In The science of self-report: implications for research and practice. Edited by: Stone AA, Turkkan JS, Bachrach CA, Jobe JB, Kurtzman HS, Cain VS. 2000, Lawrence Erlbaum Associates: Mahwah, NJ Vaur L, VAisse B, Genes N, Elkik F, Legrand C, Poggi L: Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial. Am J Hypertens. 1999, 12 (4): 374-380. Burke LE: Electronic measurement. In: Compliance in healthcare and research. Edited by: Burke LE, Ockene IS. 2001, Armonk, NY: Futura Publishing, 117-138. American Heart Association Monograph Series Pledger G, Hall DB: Active control equivalence studies: do they address the efficacy issue?. In: Statistical Issues in Drug Research and Development. Edited by: Peace KE. 1990, New York: Marcel Dekker, 226-238. Glaser S, Steinbach M, Opitz C, Wruck U, Kleber FX: Torsades de pointes caused by Mibefradil. Eur J Heart Fail. 2001, 3: 627-630. 10.1016/S1388-9842(01)00159-3. Weir MR, Sperling RS, Reicin A, Gertz BJ: Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003, 146 (4): 591-604. 10.1016/S0002-8703(03)00398-3. Konstam MA: Matters of the heart: Assessing the cardiovascular safety of new drugs. Am Heart J. 2003, 146: 561-562. 10.1016/S0002-8703(03)00400-9. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. CPMP Working Party on Efficacy of Medicinal Products Note for guidance III/3630/92-EN. Stat Med. 1995, 14: 1658-1682. Committee for Proprietary Medicinal Products: Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol. 2001, 52: 223-228. 10.1046/j.1365-2125.2001.01397-3.x. Gomberg-Maitland M, Frison L, Halperin JL: Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. Am Heart J. 2003, 146: 398-340. 10.1016/S0002-8703(03)00324-7.